Incyte Corporation ($INCY) Stock Forecast: Up 1.3% Today

What is Incyte Corporation?

Asset Incyte Corporation (INCY) is a biopharmaceutical company specializing in treatments in hematology, oncology, and immunology, notably with its flagship product Jakafi. The company is currently expanding its pipeline and growth strategies.

Why is Incyte Corporation going up?

INCY stock is up 1.3% on Apr 28, 2026 19:42

• Despite exceeding first-quarter earnings and revenue expectations, Incyte Corporation's stock saw a 4% decrease in pre-market trading.
• The stock decline is linked to the company's lower-than-anticipated full-year revenue guidance, sparking concerns about its future growth and performance.
• The appointment of Zimmer Biomet's CFO to a new role at Incyte may have impacted investor sentiment, prompting questions on the company's financial decisions and overall strategy.
• Investors are keeping a close eye on Incyte's capacity to sustain revenue growth, introduce new products beyond Jakafi, and enhance profitability and shareholder value.

INCY Price Chart

INCY Technical Analysis

INCY News

Earnings call transcript: Incyte Q1 2026 beats earnings expectations

Incyte Corporation reported strong Q1 2026 results, surpassing EPS and revenue forecasts, but experienced a slight premarket stock dip. The company's flagship product, Jakafi, continues to drive revenue, and its pipeline shows promising developments with multiple regulatory applications and clinical trials underway for new treatments in hematology, oncology, and immunology. Incyte reaffirmed its full-year 2026 guidance and discussed strategic plans for growth beyond Jakafi, including the potential of new product launches and an updated management team.

https://www.investing.com/news/transcripts/earnings-call-transcript-incyte-q1-2026-beats-earnings-expectations-93CH-4641622

Incyte Releases Q1 2026 Financial Results

Incyte Corporation reported strong financial results for Q1 2026, surpassing Wall Street expectations with non-GAAP diluted earnings per share of $1.81 against an estimate of $1.40. The biopharmaceutical company generated $1.27 billion in revenue, a 21.0% increase year-over-year, driven by robust demand across its portfolio, including its flagship treatment, Jakafi. Despite a mixed analyst consensus, the company demonstrated a decisive earnings beat and accelerating revenue trajectory.

https://news.alphastreet.com/incyte-releases-q1-2026-financial-results/

Zimmer Biomet Names Interim CFO as Suketu Upadhyay Departs

Zimmer Biomet has appointed Paul Stellato as interim chief financial officer following the departure of Suketu Upadhyay, who is leaving to pursue another professional opportunity at Incyte. Stellato, previously controller and chief accounting officer, will serve during the search for a permanent successor. The transition comes as Zimmer Biomet continues its growth and margin initiatives in the medical technology market, focusing on digital surgery and robotics.

https://www.citybiz.co/article/837975/zimmer-biomet-names-interim-cfo-as-suketu-upadhyay-departs/

Incyte stock falls nearly 4% despite beating first quarter estimates

Incyte Corporation's stock fell nearly 4% in pre-market trading despite beating first-quarter earnings and revenue estimates. The decline was attributed to the biopharmaceutical company's full-year revenue guidance falling significantly short of analyst projections, with a midpoint shortfall of approximately $710 million. The company reported strong performance in its key products, Jakafi, Opzelura, and the Hematology and Oncology portfolio, and announced positive Phase 3 results for povorcitinib.

https://m.investing.com/news/earnings/incyte-stock-falls-nearly-4-despite-beating-first-quarter-estimates-93CH-4641078?ampMode=1

Incyte stock falls nearly 4% despite beating first quarter estimates

Incyte Corporation reported strong first-quarter 2026 results, exceeding Wall Street expectations with adjusted EPS of $1.81 and total revenue of $1.27 billion, up 21% year-over-year. Despite this beat, the company's stock fell nearly 4% in pre-market trading because its full-year revenue guidance of $4.77 billion to $4.94 billion came in significantly below analyst consensus of $5.57 billion. CEO Bill Meury highlighted strong commercial execution and growth across its product portfolio, including Jakafi, Opzelura, and its Hematology and Oncology portfolio.

https://za.investing.com/news/earnings/incyte-stock-falls-nearly-4-despite-beating-first-quarter-estimates-93CH-4236226

Trending Today

Wheat ($WHEAT) Commodity Forecast: Up 5.2% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

Incyte Corporation ($INCY) Stock Forecast: Up 1.3% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.0% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 7.3% Today

United Parcel Service Inc. ($UPS) Stock Forecast: Down 4.9% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Down 5.2% Today

Alcoa Corporation ($AA) Stock Forecast: Down 5.1% Today

Universal Health Services Inc. ($UHS) Stock Forecast: Down 6.9% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.1% Today

Incyte Corporation Price History

07.00.2026 - INCY Stock was up 5.8%

• INCY is the ticker symbol for Incyte, a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The overall market today saw bullish movements, with the Dow and S&P 500 hitting record highs.
• ASSESSMENT:
• The bullish movement in INCY today can be attributed to the positive top-line results from its Phase III frontMIND study for Monjuvi/Minjuvi in combination with Bristol Myers’ Revlimid and R-CHOP for newly diagnosed DLBCL. This successful study meeting key goals and endpoints has likely boosted investor confidence in the company's pipeline and future prospects.
• Additionally, the exclusive license agreement with Prelude Therapeutics for the advanced clinical development of PRT2527 for oncology showcases strategic collaborations that can enhance the company's position in the market and expand its potential for growth.
• The upcoming submission of a supplemental biologics license application to the FDA for label expansion for first-line DLBCL treatment further indicates positive developments in the company's product portfolio, potentially attracting more investors seeking exposure to innovative treatments in the biopharmaceutical sector.

28.03.2026 - INCY Stock was up 1.3%

• Despite exceeding first-quarter earnings and revenue expectations, Incyte Corporation's stock saw a 4% decrease in pre-market trading.
• The stock decline is linked to the company's lower-than-anticipated full-year revenue guidance, sparking concerns about its future growth and performance.
• The appointment of Zimmer Biomet's CFO to a new role at Incyte may have impacted investor sentiment, prompting questions on the company's financial decisions and overall strategy.
• Investors are keeping a close eye on Incyte's capacity to sustain revenue growth, introduce new products beyond Jakafi, and enhance profitability and shareholder value.

28.03.2026 - INCY Stock was down 2.2%

• Despite reporting strong financial results for Q1 2026, including surpassing earnings per share and revenue expectations, INCY's stock took a hit, falling nearly 4%.
• The bearish movement can be attributed to the company's full-year revenue guidance falling short of analyst projections by approximately $710 million, leading to investor concerns about future growth prospects.
• The departure of Zimmer Biomet's CFO to pursue another opportunity at Incyte might have also influenced market sentiment, raising questions about potential impacts on financial strategies and decision-making at INCY.
• The market's reaction indicates that while the company demonstrated solid performance in the first quarter, concerns about future revenue outlook and key executive transitions contributed to the bearish trend in INCY's stock price.

19.11.2025 - INCY Stock was up 5.0%

• The strong bullish movement in Incyte's stock today could be attributed to the positive quarterly results, beating analyst EPS and revenue estimates.
• The recent approval for Minjuvi in Europe, a chemotherapy-free immunotherapy for follicular lymphoma, has likely boosted investor confidence in Incyte's oncology portfolio.
• The significant insider selling by Incyte's EVP, Michael James Morrissey, might have initially raised concerns, but the overall market sentiment seems to have focused more on the company's recent achievements and future pipeline potential.
• Incyte's upcoming presentation at the J. P. Morgan Healthcare Conference could also be generating optimism among investors regarding the company's future outlook and growth prospects.

10.01.2026 - INCY Stock was down 6.0%

• INCY reported a Q4 profit miss despite strong sales growth, leading to a negative market movement.
• The stock declined in pre-market trading due to concerns about the earnings per share miss, although revenue surpassed expectations.
• A Hold rating on INCY stock was reiterated by Truist Securities, highlighting upcoming pipeline readouts and commercial execution as significant areas of focus for the company in 2026.
• The company's conservative 2026 revenue guidance and increased R&D and launch costs impacting profitability were factors contributing to the pessimistic outlook on the stock.

10.01.2026 - INCY Stock was down 7.0%

• Incyte Corporation's stock experienced a bearish movement after reporting mixed Q4 2025 results, with a revenue beat but an earnings miss.
• Despite strong sales growth, including significant increases in Jakafi and Opzelura sales, the company's adjusted EPS fell short of expectations due to higher operating expenses.
• The market reaction indicates that investors were more focused on the earnings miss rather than the revenue beat, leading to a decline in the stock price.
• Analysts maintaining a Hold rating on the stock and highlighting upcoming pipeline readouts and commercial execution as key focuses suggest a cautious outlook on the company's performance in 2026.

10.01.2026 - INCY Stock was down 5.3%

• Today, Incyte's stock (INCY) faced a bearish movement due to specific reasons:
• Despite surpassing revenue expectations for Q4 CY2025 at $1.51 billion, the company's non-GAAP profit of $1.80 per share fell short of analyst predictions, leading to investor dissatisfaction.
• The 2026 revenue forecast of $4.77 billion to $4.94 billion, which is conservative compared to current analyst consensus, along with heightened R&D and launch expenses affecting profitability, influenced the negative market outlook.
• Despite emphasizing significant core business growth and pipeline advancements, conflicting financial results and insider sales activity raised investor concerns and triggered a stock sell-off.
• Investors had anticipated more robust outcomes, especially in terms of profitability, resulting in a 4.4% pre-market trading decline.

06.00.2026 - INCY Stock was up 4.1%

• Positive top-line data from its Phase III frontMIND trial for tafasitamab in combination with lenalidomide and R-CHOP met primary and key secondary endpoints, boosting investor confidence in the company's pipeline.
• Plans to submit a supplemental biologics license application for tafasitamab as a first-line therapy for DLBCL in 2026 signify potential future revenue streams and market expansion for Incyte.
• Analysts' caution about market share due to competitive landscape may present challenges, but the strong trial results have the potential to reshape Incyte's investment narrative and reduce its reliance on existing products like Jakafi.
• Overall, positive trial outcomes and future regulatory filings have spurred investor optimism and contributed to the bullish movement in Incyte's stock today.

08.11.2025 - INCY Stock was down 1.4%

• Today's downward movement in Incyte Corporation's stock could be linked to profit-taking by investors following a string of positive developments.
• In spite of recent upgrades and promising clinical data shared at a medical conference, the stock may have dipped as investors secured profits.
• The initial surge in stock price due to increased investments from institutional shareholders like American Century Companies Inc. and Invesco Ltd. might have been counterbalanced by subsequent selling pressure.
• The broader market sentiment towards biopharmaceutical firms and the healthcare industry could have also played a role in the stock's decline today.

06.01.2026 - INCY Stock was up 5.0%

• Increase in price target for Incyte to $110 from $102, along with other analysts adjusting their targets, has created a positive outlook for the stock, leading to a bullish movement.
• Expectations of a strong Q4 earnings report, driven by robust sales of its key drugs and a high probability of an earnings beat, have likely contributed to investor optimism.
• The positive opinion from CHMP of the EMA for Incyte's Zynyz in treating a rare cancer indication opens up new market opportunities, further boosting investor confidence in the company's growth potential.
• The upcoming earnings call on February 10 to unveil Q4 and full-year 2025 results adds anticipation and excitement among investors, fueling the bullish sentiment towards Incyte's stock.

07.00.2026 - INCY Stock was up 5.2%

• Positive Phase III trial results for tafasitamab in combination with lenalidomide and R-CHOP for DLBCL have significantly boosted investor confidence in Incyte's potential for a new treatment option in the oncology space.
• Strategic collaborations and exclusive license agreements with Prelude Therapeutics have reshaped Incyte's pipeline, indicating a promising future for the company's oncology programs.
• Despite analyst caution regarding market share due to a competitive landscape, the successful trial outcomes and plans for regulatory approval have propelled INCY stock to gain traction among investors, leading to today's bullish market movement.
• Overall, the optimistic news surrounding Incyte's clinical developments and strategic partnerships have fueled positive sentiment and contributed to the stock's upward momentum.

08.00.2026 - INCY Stock was down 5.1%

• INCY stock experienced a strong bearish movement despite positive Phase 3 trial results for its lymphoma drug, Monjuvi/Minjuvi.
• The bearish movement could be attributed to profit-taking by investors after a significant run-up in the stock price following the positive trial results.
• The market may also be reacting to broader sector trends or macroeconomic factors impacting biotech stocks, leading to a temporary pullback in INCY's share price.
• It's essential for investors to consider the long-term growth potential of INCY, especially with promising developments in its pipeline and successful clinical trials, despite the short-term market volatility.